… John Paolini, our Chief Medical Officer; and Eben … FDA granted KPL-387 Orphan Drug Designation for the treatment … drives collaboration expenses. ARCALYST collaboration profit grew a … Good day. Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA …

… trials. We and Sanofi are contemplating another Phase III trial … FDA approved as the first and only immunotherapy for adjuvant treatment … of biotechnology. In summary, Regeneron … Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Follow Regeneron Pharmaceuticals Inc …

… Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines … of sites for, our clinical trials; delays or difficulty in …

… FDA. In October 2025, updated data from the pivotal trial … . About Regeneron Regeneron is a leading biotechnology company that … medicine has led to numerous approved treatments … future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or …

… especially with its lead product ARCALYST for recurrent pericarditis. Looking forward … than nearly 90% of its biotechnology peers, suggesting the sector’s … toward sustainable earnings. Conclusion Kiniksa Pharmaceuticals represents the affordable growth model …

… responses.12 Clinical trials demonstrate that … Evaluation of Pharmaceuticals (2021 Trial Version)”14 … fda.gov/drugs/;news-events-human-drugs/fda-approves-first-treatment- … Kiniksa. Duration of treatment. Arcalyst (rilonacept) for Injection. 2021 …

… the treatment of obesity. The trial demonstrated … biotechnology company that invents, develops, and commercializes life-transforming medicines … regeneron.com   christina.chan@regeneron.com       TABLE 1   REGENERON PHARMACEUTICALS … sales of ARCALYST®, which are …

… cross-trial comparisons, patients taking a 4-drug … first and only FDA-approved treatment for this debilitating … of profits from ARCALYST and higher royalty … disconnect. Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Follow Regeneron Pharmaceuticals Inc. …

… 47;3 clinical trial in recurrent … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines … , our clinical trials; delays or …

… July 29, 2025 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations … Phase III pivotal trial, supporting FDA approval of ARCALYST in recurrent … good persistence from the Medicare Part D patients who … efforts to shorten the treatment journey for patients by …